On October 13, Wharton Human-AI Research and GBK Collective released the fourth edition of their annual enterprise AI study, The Adaptive Advantage: Who’s Winning with AI and How (Wharton & GBK, 2026a).…
From Pyramid to T, Part 3: What the T-Shaped Organization Means for BD Professionals Using ADP payroll data covering millions of US workers, researchers at Stanford found that employment of…
From Pyramid to T, Part 2: How to Get There, and What Has to Be True In Part 1, I argued that the BD org chart is moving from a…
From Pyramid to T, Part 1: Why AI Is Reshaping the Business Development Organization Every BD&L course I teach has, at some point, at least one participant bring up the…
We all know what “Death by PowerPoint” means. It’s that fifty-slide odyssey where, somewhere around slide 34, the email simply must be checked, the LinkedIn app buzzed (Did it really?),…
Where AI Doesn’t Change the Math — Part B Part A argued that AI-assisted diligence widens the top of the in-licensing funnel. More opportunities can get real evaluation without proportionally…
How AI Changes the Math of In-Licensing — Part A Every licensing executive has seen some version of this chart. AbbVie disclosed its own numbers a few years back: roughly…
Will AI create more assets than pharma can absorb? AI is often discussed as a solution to pharmaceutical research and development productivity. It may be. Certainly Big Pharma thinks so,…
After ~six months of integrating AI into our workflows at Lacerta Bio (plus building a few custom tools for ourselves and our clients), I've developed what I call the "intern-to-partner…
Introduction In Part I of this series, we introduced the idea that drug candidates emerging from artificial intelligence may have to be valued differently than those emerging from more traditional…